ACTH(4–10) Adamantyl Analog

Molecular Profile

Type

Synthetic peptide (ACTH fragment analog, 9 residues)

Molecular formula

C50H69N11O11S

Molecular weight

1032.23 g/mol

Amino acids

9

Sequence

Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-NH₂

Modification

N-terminal acetylation; C-terminal amidation; C-terminal adamantylglycine residue (adamantane cage moiety).

Mechanism & Target Class

A synthetic peptide corresponding to the ACTH(4–10) fragment scaffold, sharing the core Met-Glu-His-Phe-Pro-Gly-Pro sequence of Semax and extending it with Ala-Gly at the C-terminus. The terminal residue carries an adamantyl moiety — a rigid lipophilic cage incorporated in related peptide analogs to investigate how hydrophobic substitutions affect membrane penetration and proteolytic stability. N-terminal acetylation and C-terminal amidation cap the sequence, structural modifications studied for their effect on conformational stability and resistance to enzymatic degradation in tissue-preparation assays.

Storage & Handling

Lyophilized

Store refrigerated or at −20 °C, protected from light; use desiccant as needed.

Handling

Avoid repeated freeze-thaw cycles; protect from light and microbial contamination; prepare fresh aliquots for each experiment.

References (20)

1. Reviews

   1

   Markov DD, Dolotov OV, Grivennikov IA (2023). Int. J. Mol. Sci.

   DOI: 10.3390/ijms24076664

2. Primary research

   2

   Radchenko AI, Sobolevsky OI, et al. (2025). Acta Naturae

   DOI: 10.32607/actanaturae.27808

3. 3

   Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F (2022). ACS Chem. Neurosci.

   DOI: 10.1021/acschemneuro.1c00707PubMed 35080861

4. 4

   Sudarkina OY, Remizova JA, et al. (2021). Int. J. Mol. Sci.

   DOI: 10.3390/ijms22126179

5. 5

   Dolotov OV, Karpenko EA, Seredenina TS, et al. (2006). J. Neurochem.

   DOI: 10.1111/j.1471-4159.2006.03658.xPubMed 16524382

6. 6

   Medvedeva EM, Dergunova LV, Filippenkov IB, et al. (2014). BMC Genomics

   DOI: 10.1186/1471-2164-15-228PubMed 24666732

7. 7

   Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Brain Res.

   DOI: 10.1016/j.brainres.2006.07.108PubMed 16996037

8. 8

   Shadrina MI, Dolotov OV, Grivennikov IA, et al. (2001). Neurosci. Lett.

   DOI: 10.1016/s0304-3940(01)01994-2PubMed 11457573

9. 9

   Agapova TY, Agniullin YV, Shadrina MI, et al. (2007). Neurosci. Lett.

   DOI: 10.1016/j.neulet.2007.02.042PubMed 17353092

10. 10

    Shadrina M, Kolomin T, Agapova T, et al. (2009). J. Mol. Neurosci.

    DOI: 10.1007/s12031-009-9270-zPubMed 19662538

11. 11

    Storozhevykh TP, Tukhbatova GR, Senilova YE, et al. (2007). Bull. Exp. Biol. Med.

    DOI: 10.1007/s10517-007-0192-xPubMed 18239779

12. 12

    Grivennikov IA, Dolotov OV, Zolotarev YA, et al. (2008). Restor. Neurol. Neurosci.

    DOI: 10.3233/rnn-2008-00419PubMed 18431004

13. 13

    Eremin KO, Kudrin VS, Saransaari P, et al. (2005). Neurochem. Res.

    DOI: 10.1007/s11064-005-8826-8PubMed 16362768

14. 14

    Bashkatova VG, Koshelev VB, Fadyukova OE, et al. (2001). Brain Res.

    DOI: 10.1016/s0006-8993(00)03324-2PubMed 11245825

15. 15

    Dmitrieva VG, Kolomin TA, Shadrina MI, et al. (2009). Cell Mol. Neurobiol.

    DOI: 10.1007/s10571-009-9432-0PubMed 19633950

16. 16

    Medvedeva EV, Dmitrieva VG, Limborska SA, et al. (2017). Mol. Genet. Genomics

    DOI: 10.1007/s00438-017-1297-1PubMed 28255762

17. 17

    Filippenkov IB, Stavchansky VV, Denisova AE, et al. (2020). Genes

    DOI: 10.3390/genes11060681PubMed 32580520

18. 18

    Dergunova LV, Filippenkov IB, Stavchansky VV, et al. (2021). Mol. Biol.

    DOI: 10.1134/s0026893321010040PubMed 34097675

19. 19

    Stavchansky VV, Yuzhakov VV, Sevan'kaeva LE, et al. (2024). Curr. Issues Mol. Biol.

    DOI: 10.3390/cimb46030133PubMed 38534749

20. 20

    Filippenkov IB, Shpetko YY, Stavchansky VV, et al. (2024). Biomedicines

    DOI: 10.3390/biomedicines12122830PubMed 39767736